Goodsurance
ES

Drug prices & Part D

Medicare Will End Its Part D Premium Subsidy After 2026, Pointing to Higher Standalone Drug Plan Costs in 2027

CMS announced the Part D Premium Stabilization Demonstration will expire at year's end, removing a cushion that KFF estimates kept average standalone prescription drug plan premiums about 16 dollars per month below what market conditions alone would have produced.

By the Goodsurance editorial teamJuly 20, 2026

The Centers for Medicare and Medicaid Services announced on July 28, 2026, that it will not extend the Part D Premium Stabilization Demonstration past contract year 2026. The program, launched by the Biden administration in January 2025, gave voluntary subsidies to standalone prescription drug plan sponsors to limit premium increases during the first years of the redesigned Part D benefit created by the Inflation Reduction Act. CMS said plan sponsors now have enough experience with the new benefit to set prices without it.

With the demonstration ending, plan sponsors will price their 2027 coverage under ordinary market conditions. CMS simultaneously published the 2027 national average monthly bid amount at 296.05 dollars and the 2027 base beneficiary premium at 41.33 dollars. The bid amount rose roughly 24 percent from the 2026 level, signaling that plans expect higher drug spending without the federal cushion. The 41.33 dollar base premium is the largest rise the law allows, since it caps yearly increases at 6 percent through 2029. The Medicare Rights Center warned that premiums for some plans could rise well above that cap, because the cap does not limit what each plan charges.

The subsidy that kept standalone Medicare drug plan premiums artificially low is ending. Standalone plan holders could see higher monthly costs in 2027.

KFF estimated that the demonstration lowered average standalone plan premiums by about 16 dollars per month in 2026. Without a comparable program in 2027, standalone plan enrollees face the prospect of meaningfully higher monthly costs. CMS said it expects most enrollees will see increases of fewer than 10 dollars per month, though analysts noted that actual outcomes will vary by plan and geography.

About one in four Medicare beneficiaries who use drug coverage rely on standalone plans rather than getting coverage through a Medicare Advantage plan. The Medicare Open Enrollment period, October 15 through December 7, gives those enrollees the opportunity to compare 2027 options before the changes take effect. CMS said it would release the full list of 2027 plans and final average premiums in mid to late September.

In plain words

Since January 2025, the federal government has paid extra money to certain drug plan companies to keep monthly premiums low. That extra payment ends December 31, 2026. In 2027, drug plans will set their own prices without the government cushion. KFF says the support reduced the average premium by about 16 dollars a month in 2026. If you have a standalone drug plan (not one through Medicare Advantage), your monthly cost could go up in 2027. How much depends on which plan you choose. The Medicare open enrollment window is October 15 through December 7. Comparing plans during that time can help you find a lower price for next year.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026

Drug prices & Part D

Study: Medicare Drug Price Negotiations Cut Costs for Most Enrollees, but Not for Those Already Hitting the Annual Spending Limit

A research letter in Annals of Internal Medicine finds that patients on six of the first ten negotiated Part D drugs saw out-of-pocket costs fall 26 to 49 percent, while patients on the three highest-priced negotiated drugs saw no additional benefit because they were already reaching the annual cap.

October 24, 2026

Drug prices & Part D

A Customs Rule That Would Have Complicated Drug Orders From Canada Is Delayed Three Months

A new paperwork and bonding requirement for international mail containing medications was set to take effect today but was pushed back to January 20, 2027, preserving a cost-saving pathway that many Medicare beneficiaries and other older adults have come to rely on.

October 22, 2026

Drug prices & Part D

CMS Proposes Eliminating the 1-Dollar Generic Drug Copay for the Lowest-Income Medicare Dual Enrollees

A proposed rule published today in the Federal Register would bring the Part D generic drug copayment to zero for full-benefit dual eligible individuals at or below the Federal Poverty Level, starting in 2028.

October 20, 2026

Drug prices & Part D

Drug Maker Agrees to Pay 4 Million Dollars for Billing Medicare Part D for an Eye Drop That Had Gone Over the Counter

Somerset Lifesciences continued labeling a generic antihistamine eye drop as prescription-only for more than three years after its brand equivalent became available without a prescription, causing Medicare to pay pharmacy claims for a drug the program does not cover.

October 19, 2026